作者：
Nina M S,Gustafsson [1]
;
Katarina,Färnegårdh [2]
;
Nadilly,Bonagas [3]
;
Anna Huguet,Ninou [4]
;
Petra,Groth [5]
;
Elisee,Wiita [5]
;
Mattias,Jönsson [3]
;
Kenth,Hallberg [5]
;
Jemina,Lehto [5]
;
Rosa,Pennisi [3]
;
Jessica,Martinsson [6]
;
Carina,Norström [7]
;
Jessica,Hollers [5]
;
Johan,Schultz [3]
;
Martin,Andersson [8]
;
Natalia,Markova [7]
;
Petra,Marttila [3]
;
Baek,Kim [9]
;
Martin,Norin [3]
;
Thomas,Olin [7]
;
Thomas,Helleday [10]
作者单位：
Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet, 171 21, Stockholm, Sweden. nina.gustafsson@scilifelab.se.
[1]
Kancera AB, Karolinska Science Park, 171 48, Solna, Sweden. nina.gustafsson@scilifelab.se.
[2]
Kancera AB, Karolinska Science Park, 171 48, Solna, Sweden.
[3]
Drug Discovery and Development Platform, Science for Life Laboratory, Department of Organic Chemistry, Stockholm University, Box 1030, S-171 21, Solna, Sweden.
[4]
Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet, 171 21, Stockholm, Sweden.
[5]
SARomics Biostructures AB, Medicon Village, SE-223 81, Lund, Sweden.
[6]
Sprint Bioscience, 141 57, Huddinge, Sweden.
[7]
Department of Sciences, Roma Tre University, 446 00146 Rome, Italy.
[8]
Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, USA.
[9]
Malvern Instruments, 752 28, Uppsala, Sweden.
[10]
Department of Pharmacy, Kyung-Hee University, 02447, Seoul, South Korea.
[11]
Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet, 171 21, Stockholm, Sweden. t.helleday@sheffield.ac.uk.
[12]
Sheffield Cancer Centre, Department of Oncology and Metabolism, University of Sheffield, S10 2RX, Sheffield, UK. t.helleday@sheffield.ac.uk.
[13]
DOI
10.1038/s41467-018-06287-x
PMID
30250201
发布时间
2024-03-31
换一批
换一批
